Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
16 December 2017 |
Main ID: |
NCT00287729 |
Date of registration:
|
06/02/2006 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
|
Scientific title:
|
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis |
Date of first enrolment:
|
April 2006 |
Target sample size:
|
344 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT00287729 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
United States
| | | | | | | |
Key inclusion & exclusion criteria
|
Primary Inclusion criteria:
- diagnosis of idiopathic pulmonary fibrosis
- 40 to 80 years of age
- Forced Vital Capacity = 50% predicted value
- carbon monoxide diffusing capacity (DLco) = 35% predicted value
- either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) = 90%
predicted value
- no improvement in past year
- able to walk 150 meters in 6 minutes and maintain saturation = 83% while on no more
than 6 liters per minute supplemental oxygen
Primary Exclusion criteria:
- unable to undergo pulmonary function testing
- evidence of significant obstructive lung disease or airway hyper-responsiveness
- in the clinical opinion of the investigator, the patient is expected to need and be
eligible for a lung transplant within 72 weeks of randomization
- active infection
- liver disease
- cancer or other medical condition likely to result in death within 2 years
- diabetes
- pregnancy or lactation
- substance abuse
- personal or family history of long QT syndrome
- other IPF treatment
- unable to take study medication
- withdrawal from other IPF trials
Age minimum:
40 Years
Age maximum:
80 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Idiopathic Pulmonary Fibrosis
|
Intervention(s)
|
Drug: Pirfenidone
|
Drug: Placebo
|
Primary Outcome(s)
|
Absolute Change in Percent Predicted Forced Vital Capacity(FVC)
[Time Frame: Baseline to week 72]
|
Secondary Outcome(s)
|
Progression-free Survival
[Time Frame: Baseline to Week 72]
|
Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs
[Time Frame: Baseline to Week 72]
|
Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test
[Time Frame: Baseline to Week 72]
|
Worsening of IPF
[Time Frame: Time to acute IPF exacerbation, IPF-related death, lung transplant or respiratory hospitalization, whichever comes first.]
|
Change in Dyspnea Score
[Time Frame: Baseline to Week 72]
|
Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity
[Time Frame: Baseline to week 72]
|
Change in the Six-Minute Walk Test (6MWT) Distance
[Time Frame: Baseline to Week 72]
|
Secondary ID(s)
|
Capacity 1
|
PIPF-006
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
|